Skip To Main Content
Taylor Engdahl on Muck Rack

Taylor Engdahl

Nashville, Washington, D.C.
As seen in: Nature, American Society for Microbiology (ASM), VUMC Reporter
Covers:  infectious diseases, vaccines, COVID-19, pandemics, grad school
Scientific advisor @DARPA. Passionate about all things pandemic preparedness. @VUMC_Vaccines alum. She/her/hers. (views my own)

Get in touch with Taylor

Contact Taylor, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Taylor Engdahl’s Biography

Read Full Bio →

Ph.D. candidate at Vanderbilt University

Taylor Engdahl’s Journalist Portfolio

SARS-CoV-2 is changing. What does that mean for vaccines and treatments?

SARS-CoV-2 is changing. What does that mean for vaccines and treatments?

Viruses exist in a constant arms race with the host's immune system. As the immune system fights off a virus,…

View article →
The lonely marathon run that transformed my approach to graduate school

The lonely marathon run that transformed my approach to graduate school

In 2020, I had one big personal goal: to run my first marathon, a Rock n' Roll series race in Nashville, Tenn…

View article →

Articles

Comparison of uridine and N1-methylpseudouridine mRNA platforms in development of an Andes virus vaccine - Nature Communications

|
By Ivan Kuzmin, Perry T. Wasdin, Taylor Engdahl, Ivelin S. Georgiev, Robert Abbott
| Nature Verified
Abstract The rodent-borne Andes virus (ANDV) causes a severe disease in humans. We developed an ANDV mRNA vaccine based on the M segment of the viral genome, either with regular uridine (U-mRNA) or N1-methylpseudouridine (m1Ψ-mRNA). Female mice immunized by m1Ψ-mRNA developed slightly greater germinal center (GC) responses than U-mRNA-immunized mice.
Open in Who Shared Issue with article?

Computationally restoring the potency of a clinical antibody against Omicron - Nature

|
By Thomas Desautels, Kathryn T Arrildt, Adam Zemla, Seth J. Zost, Elad Binshtein, Bernadeta Dadonaite, Taylor Engdahl, Laura S. Handal, Bradley Whitener, James Case, Larissa B. Thackray, Jesse Bloom, Michael Diamond Verified, Robert Carnahan
| Nature Verified
Abstract The COVID-19 pandemic underscored the promise of monoclonal antibody-based prophylactic and therapeutic drugs1,2,3 and revealed how quickly viral escape can curtail effective options4,5. When the SARS-CoV-2 Omicron variant emerged in 2021, many antibody drug products lost potency, including Evusheld and its constituent, cilgavimab4,5,6.
Open in Who Shared Issue with article?

Mechanistic basis for potent neutralization of Sin Nombre hantavirus by a human monoclonal antibody - Nature Microbiology

|
By Robert Stass, Taylor Engdahl, Rachael M. Wolters, Laura S. Handal
| Nature Verified
Cell lines Expi293F cells (human, female origin) were cultured in suspension at 37 °C in 8% CO2 with shaking at 125 r.p.m. in Freestyle F17 Expression Medium (Gibco) supplemented with 10% Pluronic F-68 and 200 mM of l-glutamine. ExpiCHO cells (hamster, female origin) were cultured in suspension at 37 °C in 8% CO2 with shaking at 125 r.p.m. in ExpiCHO Expression Medium (Thermo Fisher).
Open in Who Shared Issue with article?
See all 7 articles